Last reviewed · How we verify
NCT04292587
Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
trial in Hirsutism in 5,861 participants. Status unknown.
30 September 2020
Quick facts
| Lead sponsor | Istanbul Medeniyet University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,861 |
| Start date | 3 February 2020 |
| Primary completion | 30 September 2020 |
| Estimated completion | 30 September 2020 |
| Sites | 26 locations across Turkey (Türkiye) |
Conditions studied
- Hirsutism — all drugs for Hirsutism →
Sponsor
Istanbul Medeniyet University
Who can join
Adults 18 to 45, female only, with Hirsutism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hirsutism is defined as the excessive presence of terminal hairs in the androgen-sensitive areas of the female body, and it is one of the frequent reasons for presenting to dermatology outpatient clinics. Hirsutism influences 5% to 10% of women around the world and leads to psychological problems depending on ethnic and socio-cultural factors. It also causes material burden including medicines, cosmetic products and epilation procedures. The differences in the real prevalence of hirsutism in the Turkish population and the hirsutism prevalence and severity between the geographical regions of Turkey are not known. In this study, we aimed to determine the prevalence of hirsutism in women at the reproductive age within Turkey. The geographical regions of Turkey comprise seven regions and and all regions were included in this study. By considering the regions where ethnic differences were high including the east-west-south and north of our country, we aimed to find an answer to the question of whether there were differences in terms of the prevalence and severity of hirsutism among these regions. A comprehensive study aiming to determine the prevalence of hirsutism in Turkey has not been conducted.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04292587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Istanbul Medeniyet University trials
Trials by the same sponsor.
- NCT07478380 — Transcutaneous pO₂ Monitoring in PICU · recruiting
- NCT07368244 — Turkish Translation and Content Validity of the Nottwil Environmental Factors Inventory (NEFI) in Persons With Spinal Co · recruiting
- NCT07179731 — Comparison of the Effects of External Oblique Intercostal Plane Block, Subcostal Transverse Abdominis Plane Block, and T · NA · not yet recruiting
- NCT07241455 — Validity of the Children's Chelsea Critical Care Physical Assessment Tool (cCPAx-TR) in Turkish Pediatric Intensive Care · completed
- NCT07426497 — Osteopathic Manual Therapy vs Ganglion Impar Block for Chronic Coccydynia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04292587 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Medeniyet University
- Last refreshed: 3 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing